The importance of dysmorphology in the identification of new human teratogens

Authors

  • Kenneth Lyons Jones,

    Corresponding author
    • Department of Pediatrics, University of California San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0828.
    Search for more papers by this author
    • Kenneth Lyons Jones, M.D. is a pediatrician, dysmorphologist, and teratologist whose interests are focused on the clinical delineation of birth defects and the etiology and developmental pathogenesis of structural anomalies. He is Professor of Pediatrics, University of California, San Diego, School of Medicine and Medical Director of the California Teratogen Information Service and Clinical Research Program.

  • John C. Carey

    Search for more papers by this author
    • John C Carey, M.D., MPH is a pediatrician, clinical geneticist, and dysmorphologist who has had a career long interest in the delineation of human malformation syndromes and the assessment of teratogenicity. He is Professor and Vice Chair Department of Pediatrics, University of Utah, Medical Director of the Pregnancy Risk Line, and Editor-in-chief of the American Journal of Medical Genetics, Parts A and C.


  • How to cite this article: Jones KL, Carey JC. 2011. The importance of dysmorphology in the identification of new human teratogens. Am J Med Genet Part C 157:188–194.

Abstract

The vast majority of information regarding the teratogenicity of new drugs as well as others for which adequate information is not available comes from postmarketing studies. Evaluation by a dysmorphologist of babies prenatally exposed to a particular agent has played an incredibly important role in these studies. Most of the known human teratogens have been identified by the astute clinician approach which involves the observation, documentation, and delineation of individual cases who display a novel phenotype after a particularly rare prenatal exposure. Prospective cohort studies focused on the evaluation of prenatally exposed children who have been ascertained prospectively prior to the known outcome of pregnancy and evaluated by a dysmorphologist for patterns of minor and major malformations have been equally effective. Although most human teratogens have been identified using one of these two methods, both have limitations. The purpose of this study is to set forth the extent to which a careful physical examination performed by a dysmorphologist trained in the identification of minor structural defects in development has added to our knowledge of human teratology and has been instrumental in the identification of new human teratogens. Although dysmorphologists have had a profound impact on our understanding of human teratogens. It is important to recognize that the two approaches outlined in this study must be complemented by other methodologies, such as case–control studies, that more appropriately address risks for major malformations in order to gain the full picture necessary to effectively counsel women about safety of drugs during pregnancy. © 2011 Wiley-Liss, Inc.

Ancillary